

in the diagnosis of symptomatic UTI to enable more appropriate antibiotic therapy.

15017

Monoclonal antibody use in rheumatoid arthritis: an evaluation of medical expenditure

Robert A. Kelly¹, Alice C. Ceacareanu^{1,2} and Zachary A.P. Wintrob^{1,2}
¹Hartwick College and ²ROAKETIN Inc.

ABSTRACT IMPACT: Younger patients receiving biologics for rheumatoid arthritis have higher medical expenditure. **OBJECTIVES/GOALS:** TNF inhibiting biologic disease modifying antirheumatic drugs are among the most highly regarded treatment options for rheumatoid arthritis (RA). We aimed at evaluating the medical and prescription costs associated with monoclonal antibody use vs. other RA treatment options in subjects diagnosed with RA. **METHODS/STUDY POPULATION:** Records from the Medical Panels Expenditure Survey (MEPS) database made available by the Agency for Healthcare Research and Quality were used to identify all RA subjects (n=_____). Demographics and MEPS-provided flags for RA were abstracted from the medical condition files for all the subjects surveyed (2008-2018). Prescribed biologics were identified based on generic and brand names following a manual review to detect any misspellings. Total medical expenses and prescription expenses were abstracted for all identified RA subjects. Subject were surveyed for two consecutive years, thus expenses were assessed for each of the two surveyed years. Costs were adjusted for inflation and expressed in 2018 dollars. The relationship between biologics use, cost and age or gender was evaluated by Fisher's exact test. **RESULTS/ANTICIPATED RESULTS:** Most RA subjects did not use biologics. RA was more prevalent in women than in men with no significant correlation between sex and the use of biologics in year 1, year 2, or the combined years (p=.44, p=.63, and p=.65, respectively). Biologics users were found to be significantly younger (p<.001), with a mean of 52.8 years compared to 59 years in those who did not use biologics. The 95% confidence interval was 3.7 to 8.6 years younger than non-users. Total medical and prescription costs were higher for biologics users (p<.001) in all analyses. The mean prescription cost difference was \$24,038 more per year for biologics users, and \$26,296 more total medical expenses, CI \$20,502-\$27,230 and CI \$21,947-\$30,646, respectively. There was a trend for biologics users to have higher non-prescription medical expenses (p=.05). **DISCUSSION/SIGNIFICANCE OF FINDINGS:** Interestingly, biologics non-users had some extreme outliers with expenses far higher than any biologics users, possibly due to poorly controlled RA due to age and/or comorbidities. Yet, our most interesting findings are the higher use of biologics among younger RA subjects and the elevated costs of care being driven mainly by prescriptions cost.

20201

Validating an in-car telemetry system for detecting frequency and severity of driving errors in patients with glaucoma.

Sharon Sabapathypillai, Monica Perlmutter, Manik Goel, Bradley Wilson, Mae Gordon and Anjali Bhorade
 Washington University-Saint Louis

ABSTRACT IMPACT: The car telemetry system may be an ideal method to accurately and reliably evaluate and compare at-risk driving errors between older drivers with and without glaucoma.

OBJECTIVES/GOALS: Our project aims to determine whether an in-car telemetry system used during an on-road driving evaluation can accurately and reliably evaluate driving errors in lane maintenance and visual scanning and objectively quantify the frequency and severity of these errors in glaucoma patients. **METHODS/STUDY POPULATION:** This is a single center, cross-sectional study of 180 participants (125 with glaucoma and 55 controls), ages 55 or older, who underwent a comprehensive clinical assessment, including vision, cognition, motor function, followed by an on-road evaluation by a trained occupational therapist. Driving errors were recorded through a dual method including: 1. An in-car trained occupational therapist 2. In-car telemetry system. The frequency and severity of errors in lane maintenance and visual scanning from the in-car telemetry will be assessed and compared between participants with varying severity of glaucoma and normal controls. In addition, we will compare the frequency and severity of errors in lane maintenance and visual scanning to those recorded by the in-car driving evaluator. **RESULTS/ANTICIPATED RESULTS:** We anticipate (or predict) that the in-car telemetry system will be able to detect frequency and severity of driving errors in lane maintenance and visual scanning in glaucoma participants. We also predict that participants with worsening glaucoma severity will commit more driving errors. In addition, the in-car telemetry will detect a similar frequency and severity of driving errors as the in-car driving evaluator. **DISCUSSION/SIGNIFICANCE OF FINDINGS:** The type and frequency of vision-related driving errors that place individuals at risk for a car accident is not well known. Without this critical information, it is extremely challenging to help older adults with glaucoma to be safe drivers.

46942

Risk factors, prevention, and screening practices for human papilloma virus associated cancers in Central-Eastern Puerto Rico

Lilibeth Cruz-Martinez, Darleen Gonzalez-Galarza and Wilfredo E. De Jesus-Monge
 Hospitales HIMA San Pablo

ABSTRACT IMPACT: The impact of this study is that the results may lead to the development of effective educational programs and a comprehensive cancer control program while verifying patients and medical care providers adherence and compliance with cancer clinical guidelines. **OBJECTIVES/GOALS:** The objective of this study is to assess risk factors, preventive measures, and screening practices for human papilloma virus (HPV) associated cancers in a sub-population in Central-Eastern Puerto Rico (PR). **METHODS/STUDY POPULATION:** This is a sub-analysis from an annual descriptive cross-sectional questionnaire of risk factors, preventive measures, and screening practices for cancer in PR administered at a private hospital campus using a convenience sample of healthy and non-healthy adults. **RESULTS/ANTICIPATED RESULTS:** Out of 345 enrolled subjects in 2019 for the questionnaire, 67 were enrolled by the first author, from which 66 (19%) subjects qualified for this sub-analysis for completing the study: 79% females. When analyzing HPV risk factors, 5% of the participants were smokers. Eleven percent of the subjects received the preventive HPV vaccine. Among those non-vaccinated and eligible for vaccination, 95% were willing to get it. Seventy one percent of females 21-29 years old and 97% of 30-65 years olds had age-appropriate cervical cancer screening. **DISCUSSION/SIGNIFICANCE OF FINDINGS:** Despite the low prevalence of HPV vaccination, almost all of the subjects within

the age range for HPV vaccination were willing to get it. Also, there was a lower prevalence of cervical cancer screening in females 21-29 years old when compared with 30-45 years old. In conclusion, there is a need for more education about HPV associated cancers and vaccine.

53034

Melatonin use and occurrence of respiratory illnesses

Hannah M. Bowen, Zachary A.P. Wintrob and Alice C. Ceacareanu¹Hartwick College and ²ROAKETIN Inc.

ABSTRACT IMPACT: Melatonin use could alleviate virus-induced respiratory illnesses. **OBJECTIVES/GOALS:** Melatonin was identified as a potential repurposable drug in the fight against SARS Cov-2. Its ability to attenuate some virus inoculation effects raises the question whether melatonin use could alleviate virus-induced respiratory illness. Here we evaluated the occurrence of respiratory conditions in melatonin users and non-users surveyed. **METHODS/STUDY POPULATION:** Records from the Medical Panels Expenditure Survey (MEPS) database made available by the Agency for Healthcare Research and Quality were used to evaluate whether melatonin may be associated with reduced viral respiratory disease burden. First, all subjects reporting melatonin use (1996-2017) were collected along with records for all subjects reporting respiratory diseases as identified by consolidated ICD-9/10 codes. Second, all diagnosis codes were retrieved for all individuals identified in the first step. In total there were 201,490 occurrences of the specified conditions among 180,468 unique individuals. The relative risk of specific respiratory disease occurrence was computed for melatonin users and non-users. Population estimates for melatonin use were also determined. **RESULTS/ANTICIPATED RESULTS:** Among 221 melatonin users, 132 had at least one respiratory illness. Among the 180,468 total subjects reporting at least one respiratory condition, melatonin use was associated with a lower rate of the common cold, pharyngitis, strep throat, scarlet fever, and sinusitis. Furthermore, melatonin was associated with a significantly reduced risk of common cold (RR 0.760, CI 0.587-0.985) and sinusitis (RR 0.407, CI 0.186-0.890). Due to low subject counts, the reduced risk observed for scarlet fever and strep throat was not considered significant. Melatonin users had a higher relative risk of allergic rhinitis (RR 1.393, CI 1.043-1.862) and asthma (RR 2.166, CI 1.672-2.806), probably due to melatonin active prescribing in these patients as sleep aid. **DISCUSSION/SIGNIFICANCE OF FINDINGS:** Although melatonin showed a lower relative risk of certain viral respiratory conditions, the low melatonin user numbers and their heterogeneous distribution over the time interval led to highly variable population estimates. Yet, our data suggests that melatonin may alleviate viral respiratory illness and deserves further investigation.

56600

Statin use and medical expenditure in patients with Parkinson's disease

Anthony J. Lo Piccolo¹, Alice C. Ceacareanu^{1,2} and Zachary A.P. Wintrob^{1,2}

¹Hartwick College and ²ROAKETIN Inc.

ABSTRACT IMPACT: Despite their clinical benefits reported in patients with Parkinson's, statin use is not associated with cost savings. **OBJECTIVES/GOALS:** Statins have unique lipid-lowering, anti-inflammatory and anti-oxidant benefits. Their pleiotropic benefits were shown

to decrease risk of occurrence and progression of Parkinson's disease (PD). In this study we explored whether or not statin use reflects medical or prescription cost savings. **METHODS/STUDY POPULATION:** Records from the Medical Panels Expenditure Survey (MEPS) database made available by the Agency for Healthcare Research and Quality were used to identify all PD subjects (n=613). Demographics and PD ICD9/10 codes, 332/G20, were abstracted from the medical condition files for all the subjects (1996-2018). Prescribed cholesterol drugs were identified based on generic and brand names following a manual review to detect any misspellings. Total medical expenses and prescription expenses were abstracted for all identified PD subjects. Subject were surveyed for two consecutive years, thus expenses were assessed for each of the two surveyed years. Costs were adjusted for inflation and expressed in 2018 dollars. The relationship between cholesterol drug use, cost and age or gender was evaluated by Fisher's exact test. **RESULTS/ANTICIPATED RESULTS:** Out of the 613 PD subjects identified, 421 received no cholesterol management, 15 received non-statin, 153 received a statin and 24 received a statin-based combo therapy. While the medical expenses in the general population receiving a statin are roughly three times higher than non-statin users, no significant cost difference was noticed between PD subjects receiving or not statins. However, after adjusting for age and gender, receiving statin vs. non-statin vs combo vs none was significantly associated with total expense (p=0.017) suggesting that cholesterol management decision may play a significant role. **DISCUSSION/SIGNIFICANCE OF FINDINGS:** Selection of specific cholesterol treatment may play a considerable role in the overall PD expenditure. Duration of statin treatment and type of statin are expected to play a role.

61586

Impact of Diabetes and Pre-diabetes on Prevalence of Infection with Mycobacterium tuberculosis among Household Contacts of Active Tuberculosis Cases in Ethiopia*

Alison G.C.S. Smith¹, Russell R. Kempker², Liya Wassie³, Kidist Bobosha³, Azhar Nizam⁴, Neel Gandhi^{2,4}, Matthew J. Magee⁴ and Henry M. Blumberg²

¹Emory University School of Medicine, ²Emory University Department of Medicine, ³Armauer Hansen Research Institute, Addis Ababa, Ethiopia and ⁴Emory University Rollins School of Public Health

ABSTRACT IMPACT: This work examines the association between diabetes mellitus and latent tuberculosis infection among a cohort of household contacts exposed to active tuberculosis in Ethiopia, focusing attention on the need for further translational research to determine the mechanisms of susceptibility to Mycobacterium tuberculosis infection among individuals with diabetes and pre-diabetes. **OBJECTIVES/GOALS:** Diabetes mellitus (DM) is an established risk factor for active TB disease, but there is limited understanding of the relationship of DM and latent tuberculosis (LTBI). We sought to determine the relationship between DM or pre-DM with LTBI among household or close contacts (HHCs) of active TB cases in Ethiopia. **METHODS/STUDY POPULATION:** We conducted a cross-sectional study of the HHCs of index active TB cases enrolled in an ongoing TB Research Unit (TBRU) study in Addis Ababa, Ethiopia. HHCs of individuals with laboratory-confirmed TB had QuantiFERON[®]-TB Gold Plus (QFT) and glycated hemoglobin (HbA1c) tests performed. LTBI was defined as a positive QFT and lack of symptoms. HbA1c results were used to define no DM (HbA1c <5.7%), pre-DM (HbA1c 5.7-6.5%), and DM (HbA1c >6.5% or prior history of diabetes). Logistic regression was used to